Skip to main content
MyPART - My Pediatric and Adult Rare Tumor Network
 

MyPART Publications

MyPART promises to share new research and data with the entire rare tumor community and the world. MyPART doctors and researchers publish their findings from laboratory experiments and clinical studies and write about their perspectives on rare tumor research. Read the publication summaries below to learn more about the MyPART team’s research projects and thoughts on rare tumors.

2021 Publications 

Fuller SN, Shafiei A, Venzon DJ, Liewehr DJ, Mauda Havanuk M, Ilanchezhian MG, Edgerly M, Anderson VL, Levy EB, Hoang CD, Jones EC, Reilly KM, Widemann BC, Wood BJ, Bagheri H, Del Rivero J. Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Curr Oncol, 2021. 28(6): 4357–4366. doi: 10.3390/curroncol28060370.

Keywords: Adrenocortical carcinoma (ACC), metastasis

Summary: Adrenocortical carcinoma (ACC) is a type of rare, aggressive endocrine tumor that grows in the adrenal glands and has a poor prognosis. In 25-30% of patients diagnosed with ACC, the cancer has already spread to other parts of the body (metastasized), most commonly to the liver, lung, and bone. The growth rate of metastasized tumors can be used to inform treatment and predict outcomes. This study used a method of volumetric segmentation, a more accurate way to determine the size of tumors compared to standard imaging analysis techniques, to measure the growth rate of metastatic ACC tumors in the liver, lung, and lymph nodes of 12 patients. This study found that tumors in the liver grew faster than tumors in the lung or lymph nodes, suggesting that metastases to the liver should be monitored to help guide treatment for patients with metastatic ACC.

Gross AM. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example. Curr Probl Cancer, 2021. 45(4):100769. doi: 10.1016/j.currproblcancer.2021.100769.

Keywords: Rare diseases, clinical trial design, external control data

Summary: Clinical trials for rare diseases, including rare cancers, are difficult to conduct for several reasons, with one of the most prominent reasons being the small number of patients available to participate in trials. This paper explains why the traditional randomized controlled clinical trial design does not work for rare disease populations where there are few patients who are usually geographically spread far apart, making it difficult to conduct a trial at a single institution or a trial with a control or “placebo” arm. This article discusses how real-world data, such as data collected through observational studies like natural history studies, patient registries, or other trials, can be used as external control data to help accelerate the approval of treatments. This article also discusses the US Food and Drug Administration (FDA) draft guidance published in 2019, “Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics,” which supports using external control data to accelerate clinical trials in rare disease populations. The case study of the successful use of external controls in the approval of selumetinib, the first drug approved to treat children 2 years and older with Neurofibromatosis type 1 and inoperable nerve tumors, is also presented.

Okafor C, Hogan J, Raygada M, Thomas BJ, Akshintala S, Glod JW, Del Rivero J. Update on Targeted Therapy in Medullary Thyroid Cancer. Front Endocrinol (Lausanne), 2021. doi: 10.3389/fendo.2021.708949.

Keywords: Medullary thyroid cancer (MTC), tyrosine kinase inhibitors (TKIs)

Summary:  Medullary thyroid cancer (MTC) is a type of rare neuroendocrine tumor that accounts for about 2-4% of thyroid cancer cases. Tyrosine kinase inhibitors (TKIs) provide treatment options for patients with MTC caused by mutations in the RET gene, but patients with tumors resistant to TKIs or tumors driven by mutations other than RET have fewer treatment options. This paper describes the different types of TKIs and how they target MTC tumors caused by mutations in RET. This paper also outlines potential strategies for treating MTC caused by mutations in the RAS gene. Other treatment options for MTC described in this paper include peptide receptor radionuclide therapy and immunotherapy. The paper discusses opportunities for future studies of pathways leading to MTC resistance that may inform clinical trial design and lead to potential new treatments. 

2020 Publications

Fuller S, Del Rivero J, Venzon D, Ilanchezhian M, Allen D, Folio L, Ling A, Widemann B, Fontana JR, Glod J. Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B. J Clin Endocrinol Metab, 2020.  105(9): 2919-2928. doi: 10.1210/clinem/dgaa296.

Keywords: Multiple endocrine neoplasia 2B (MEN2B), Medullary thyroid cancer (MTC)

Summary: Multiple Endocrine Neoplasia 2B (MEN2B) is a rare cancer predisposition syndrome that causes visible changes in the body (like bumps on the lips, eyelids and tongue and having long arms, legs, and fingers) and can lead to the development of medullary thyroid cancer. This study is the first to look at how the lungs function in people with MEN2B. Researchers looked at pulmonary function tests (a type of test that looks at how well the lungs are working) and imaging scans in a small group of young people with MEN2B and found changes in the lungs, called abnormalities. Most people in the study showed changes in the ability of their lung tissue to move gasses across the tissue and into blood vessels, called diffusion abnormalities. Some people showed small structures called cysts in the lungs. The researchers need to do more studies to find out why these changes are happening. 

Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options Oncol, 2020. 21(11):85. doi: 10.1007/s11864-020-00787-z.

Keywords: Pheochromocytoma, paraganglioma, endocrine tumors

Summary: Pheochromocytomas and paragangliomas are rare endocrine tumors that affect about 1 in 300,000 people and can spread to other parts of the body (called metastatic disease) in about 35% of people with these tumors. The tumors cause the overproduction of certain hormones in the body, which can cause a variety of different symptoms. There is currently no cure for metastatic pheochromocytomas or paragangliomas. These tumors can be divided into three groups depending on the types of gene mutations in the tumor: pseudohypoxia, kinase signaling, and Wnt signaling. Depending on which group the tumor falls into, certain therapies may be more effective at treating the tumor. This paper describes the different types of potential treatment options, which include inhibitors, immunotherapies, and radiotherapies, for each of the three groups of tumors. Some of these treatments are already approved for other types of rare solid tumors. Clinical trials are testing some of these treatments in people with pheochromocytomas and paragangliomas. New treatments are necessary to improve the quality of life and overall survival of people with pheochromocytomas and paragangliomas. 

Ilanchezhian M, Khan S, Okafor C, Glod J, Del Rivero J. Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2. Horm Metab Res, 2020. 52(8):588-597. doi: 10.1055/a-1145-8479.

Keywords: Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2)

Summary: Medullary thyroid carcinoma (MTC) is a type of rare endocrine tumor making up about 2% of thyroid cancers in the US. About 25% of MTC cases are the result of the genetic tumor predisposition syndrome, multiple endocrine neoplasia type 2A (MEN2A) or 2B (MEN2B), which can be hereditary (passed down from parent to child). This article discusses the potential treatment options for people with MTC and MEN2. The first line of treatment is usually the removal of the thyroid (thyroidectomy) or the use of tyrosine kinase inhibitors. Several other treatments are being studied, including peptide receptor radionucleotide therapy (PRRT) and immunotherapy.

Shetty I, Fuller S, Raygada M, Merino MJ, Thomas BJ, Widemann BC, Reilly KM, Pacak K, Del Rivero J. Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma. Endocrinol Diabetes Metab Case Rep, 2020. doi: 10.1530/EDM-19-0147.

Keywords: Adrenocortical carcinoma (ACC), pheochromocytoma

Summary: Adrenocortical carcinoma (ACC) is a rare, aggressive tumor that forms in the adrenal gland. Diagnosing ACC is difficult and requires specific pathology tests to determine the correct diagnosis. This paper discusses the case of a 57-year-old woman who was originally diagnosed as having a pheochromocytoma, another type of rare endocrine tumor, at age 51. Several years later, her tumor returned and was studied by imaging and biopsy tests. One institution diagnosed her with metastatic pheochromocytoma while another institution diagnosed her with ACC. When she came to the NIH, her diagnosis of ACC was confirmed after undergoing multiple tests. This case demonstrated the importance of using a multi-disciplinary approach, including genetic testing and pathology studies, for correctly diagnosing ACC, which can inform treatment options for the patient.

2019 Publications 

Reilly KM. Sharing data for the benefit of children with cancer. In: Buckley A (ed). On Medicine. BMC, 2019.

Keywords: Childhood cancer, data sharing, childhood cancer data initiative (CCDI)

Summary: Cancer is rarer in children than adults, generally, yet children with cancer are 20 times more likely to participate in clinical trials. Because all childhood cancers are rare, it is important that all available data from clinical trials be used to find new treatments. But, taking advantage of data from different studies can be hard because of barriers to finding, sharing, and combining data. To help solve these problems, the NCI is working on several new projects to make childhood cancer research easier. These projects include MyPART, the Childhood Cancer Data Initiative, and improving biobanking for childhood cancers. The entire pediatric cancer research community must do their part to help lower the barriers to data sharing and finding cures.

  • Posted:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “MyPART Publications was originally published by the National Cancer Institute.”